GLUT1 Deficiency Disorder and the Ketogenic Diet

GLUT1 Deficiency Disorder and the Ketogenic Diet

GLUT1 Deficiency Disorder and the Ketogenic Diet Main Image

Glucose serves as a vital energy source for the brain, playing a crucial role in sustaining its functions. However, the inherent polarity of glucose poses a challenge, as it cannot freely traverse the blood-brain barrier. To breach this barrier and reach brain cells, glucose relies on specific transporters, with GLUT1 (facilitated glucose transporter type I) emerging as a key player in this intricate process [2].

In the physiological landscape, adults allocate approximately 20% of their total body glucose for brain metabolism during periods of rest. In contrast, the demand for glucose in the developing brains of children is markedly higher, accounting for up to 80% of whole-body glucose utilization. This staggering demand is three to four times greater than the glucose utilization observed in adults. Such heightened reliance underscores the critical role glucose plays in supporting the rapid growth and development of the juvenile brain [1].

Given the paramount importance of glucose in this context, any disruption or reduction in its supply to the developing brain can have profound consequences, significantly impairing both brain function and overall cognitive development in children. The GLUT1 transporter assumes a pivotal role in facilitating this glucose transfer into the brain. A deficiency in this transporter mechanism can result in a cerebral “energy crisis,” creating a scenario where the brain is deprived of the energy it requires for optimal functioning.

GLUT1-Deficiency syndrome

Presentation of GLUT1 Transporter Deficiency

In 1991, a rare genetic disorder was first described where infants presented with developmental delays, microcephaly, hypotonia, motor development problems, and low cerebrospinal fluid glucose concentrations (hypoglycorrhachia) even in the presence of normal glycemic values, and seizures.  The cause of this disorder was found to be the absence of the GLUT1 transporter protein  [3, 4, 5, 6].

At birth, babies with GLUT1 deficiency syndrome may be born with a normal sized head.  However, due to the lack of glucose fueling the cerebral cells properly, the growth of the brain is slow and can result in microcephaly, developmental delays, and intellectual disability. [7]   Unfortunately, there are other GLUT1 deficiency syndrome symptoms.  Most have other pronounced neurological problems, including spasticity, ataxia, confusion, lethargy, headaches, uncontrollable muscle twitches, and difficulty with speech.  Of note, this occurs more during periods of fasting. [3]

ketogenic diet and microcephaly from glut1 transporter deficiency

Prevalence of GLUT1 Deficiency

Approximately 500 cases of GLUT1 transporter disorder have been reported since the disorder was first identified.  New estimates suggest that it may affect nearly 1 in 90,000 and that the disorder may actually be underdiagnosed since many other neurological disorders share similar symptoms.  Several conditions that were originally given other names are now recognized as mere variants of a GLUT1 deficiency include paroxysmal choreoathetosis with spasticity, ataxia, paroxysmal exercise-induced dyskinesia and epilepsy, and early-onset absence epilepsy with mild intellectual disability [7]

Ketogenic Diet and GLUT1 Deficiency

The ketogenic diet holds promising potential as an effective therapeutic approach for addressing GLUT1 deficiency, a condition where the GLUT1 transporter protein is insufficient for adequate glucose supply to the brain. An intriguing facet of the ketogenic diet lies in its utilization of ketone bodies as an alternative energy source for the brain. Notably, these ketone bodies bypass the need for the GLUT1 transporter protein, presenting a novel avenue for sustaining brain function.

Under normal circumstances, the brain relies minimally on ketones for energy. However, when immersed in a ketogenic diet, ketone bodies take center stage, supplanting glucose as the primary fuel source for cerebral metabolism. This shift is facilitated by the conversion of ketone bodies to acetyl-CoA, orchestrated by the enzymes D-β-hydroxybutyrate dehydrogenase, acetoacetate-succinyl-CoA transferase, and acetoacetyl-CoA-thiolase. Subsequently, these acetyl-CoA molecules seamlessly integrate into the Krebs Cycle within the mitochondria of brain cells, culminating in the production of adenosine triphosphate (ATP).

ATP, often regarded as the universal energy currency in living organisms, serves as the primary carrier of energy throughout diverse biological systems. In the context of the ketogenic diet, the elevation of ketone bodies and their conversion to ATP presents a pivotal mechanism by which the brain can access a reliable and GLUT1-independent energy source. This metabolic adaptation not only underscores the potential therapeutic impact of the ketogenic diet in GLUT1 deficiency but also sheds light on the intricate interplay between dietary interventions, metabolic pathways, and brain function. As we delve deeper into these connections, the ketogenic diet emerges as a promising avenue for optimizing brain energy metabolism in conditions characterized by GLUT1 deficiency.

More Evidence for the Ketogenic Diet in GLUT1 Deficiency

Some preliminary evidence suggests that the ketogenic diet will help individuals with GLUT1 Deficiency Syndrome.  One study of a family of 3 with a GLUT1 deficiency found that their seizures responded well a ketogenic diet.  It was also found that, unlike epilepsy, seizure frequency and severity of seizures worsened during fasting [3].

Because pharmaceutical treatment options are limited,  the ketogenic diet is recommended as a first-line treatment for a GLUT1 deficiency.

In Conclusion:

• The manifestation of the Glut1 defect leads to a notable physiological consequence characterized by diminished cerebrospinal fluid glucose concentrations, a condition aptly termed hypoglycorrhachia.

• Hypoglycorrhachia, stemming from the Glut1 defect, manifests in epileptic encephalopathy and movement disorders, further highlighting the far-reaching impact of this metabolic disorder on neurological functions.

• The management of Glut1 deficiency (Glut1D) presents a transformative solution in the form of a ketogenic diet. This dietary intervention introduces ketones as an alternative energy source for the brain’s metabolic processes, effectively circumventing the limitations imposed by the defective Glut1 protein.

The intricacies of Glut1 deficiency extend beyond its genetic roots, encompassing the downstream effects of reduced cerebrospinal fluid glucose concentrations, a condition known as hypoglycorrhachia. This biochemical imbalance sets the stage for profound neurological challenges, manifesting as epileptic encephalopathy and movement disorders. The intricate interplay between genetics and neurological function underscores the complexity of Glut1 deficiency, making the identification of effective treatment strategies crucial.

The ketogenic diet emerges as a life-altering therapeutic intervention for individuals grappling with Glut1 deficiency. By supplying the brain with ketones as an alternative fuel source, the ketogenic diet mitigates the adverse effects of impaired glucose transport through the defective Glut1 protein. This dietary approach not only addresses the immediate metabolic challenges but also holds the potential to transform the trajectory of neurological symptoms associated with Glut1 deficiency.

As research into the ketogenic diet continues to evolve, the scope of its life-altering applications expands beyond Glut1 deficiency. The latest findings in ketogenic diet research hint at untapped potential and additional therapeutic avenues waiting to be explored. This underscores the dynamic nature of scientific inquiry, encouraging further investigation into the broader implications of ketogenic interventions for various neurological conditions. As we delve into these uncharted territories, the ketogenic diet may unveil new possibilities, revolutionizing our approach to neurological disorders and paving the way for transformative treatments yet to be discovered.

References

1. Cremer, J. E. (1982). Substrate Utilization and Brain Development. Journal of Cerebral Blood Flow & Metabolism, 2(4), 394–407. doi:10.1038/jcbfm.1982.45]

2. Klepper, J., & Voit, T. (2002). Facilitated glucose transporter protein type 1 ( GLUT1 ) deficiency syndrome: impaired glucose transport into the brain: a review. European Journal of Pediatrics, 161(6), 295–304. doi:10.1007/s00431-002-0939-3 
]

3. Brockmann, K., Wang, D., Korenke, C. G., Von Moers, A., Ho, Y.-Y., Pascual, J. M., De Vivo, D. C. (2001). Autosomal dominant GLUT1 deficiency syndrome and familial epilepsy. Annals of Neurology, 50(4), 476–485. doi:10.1002/ana.1222 ]

4. Klepper J, Wang D, Fischbarg J, Vera JC, Jarjour IT, O’Driscoll KR, DeVivo DC. Defective glucose transport across brain tissue barriers (GLUT1): a newly recognized neurological syndrome. Neurochem Res 1999;24:587-597.]

5. Klepper J, Willemsen M, Verrips A, Guertsen E, Herrmann R, Kutzick C, Florcken A, Voit T. Autosomal dominant transmission of GLUT1-deficiency. Hum Mol Genet 200 I; 10:63-68. 
]

6. Seidner, G., Alvarez, M. G., Yeh, J.-I., O’Driscoll, K. R., Klepper, J., Stump, T. S., De Vivo, D. C. (1998). GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nature Genetics, 18(2), 188–191. doi:10.1038/ng0298-188 
]

7. Pearson, T. S., Akman, C., Hinton, V. J., Engelstad, K., & De Vivo, D. C. (2013). Phenotypic Spectrum of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS). Current Neurology and Neuroscience Reports, 13(4). doi:10.1007/s11910-013-0342-7

 

One Response

  1. […] neurological diseases like Epilepsy, GLUT1 Deficiency, Manic Depressive Bipolar Disorder, and ALS have little in common pathophysiologically, they each […]

Leave a Reply

Your email address will not be published. Required fields are marked *